INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
( Not for submission under 37 CFR 1.99)

	Application Number		10550667			
	Filing Date		2006-06-28			
	First Named Inventor	Jean-	n-Philippe Starck			
	Art Unit		1626			
	Examiner Name	Shaw	vquia Young			
	Attorney Docket Numb	er	05-765			

Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date		Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear			
	1										
If you wish to add additional U.S. Patent citation information please click the Add button.											
U.S.PATENT APPLICATION PUBLICATIONS											
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>			Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear			
	1										
If you wish to add additional U.S. Published Application citation information please click the Add button.											
				FOREIG	GN PAT	ENT DOCUM	ENTS				
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup> j		Kind Code4	Publication Date	Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T5	
/SY/	1	94/29272	wo		A1	1994-12-22	Astra Aktiebolag et al.				
/SY/	2	98/01428	wo		A1	1998-01-15	The Du Pont Merck Pharmaceutical Company				
/SY/	3	0 445 781	EP		A1	1991-09-11	Sterling Drug, Inc.				

U.S.PATENTS

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

( Not for submission under 37 CFR 1.99)

Application Number		10550667		
Filing Date		2006-06-28		
First Named Inventor Jean-F		Philippe Starck		
Art Unit		1626		
Examiner Name Shawe		quia Young		
Attorney Docket Number		05-765		

								÷.			
/SY/	4	0 022 3	317	EP	A1	1981-01-14	Fujisawa Pharmaceutical Co., Ltd.				
/SY/	5	01095	766	JP		1989-04-13	Tamanoisu KK				
/SY/	6	841 26	4	su	A1	1995-11-10	A Med. Pharmacology Res. Inst.		0		
If you wis	h to a	dd addi	ional Fore	eign Patent Docu	ument citatio	n information p	please click the Add butto	n			
				NON-I	PATENT LIT	TERATURE DO	CUMENTS				
Examiner Initials*	Cite No	(book,	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.								
/SY/	1		XP002241130, Database Crossfire Beilstein, Beilstein Institut zur Forderung der Chemischen Wissenschaftern, Franfurt am Main, Germany, Database accession no. BRN:6400176, 3 pages.								
/SY/	2	BELL,	BELL, M. et al., J. Med. Chem., 1991, Vol. 34, No. 3, pp. 1099-1110.								
/SY/	3	HOTZEL, C. et al., "Design, Synthesis, DNA-Binding and Cytotoxicity Evaluation of New Potential Combilexines", European Journal of Medicinal Chemistry, 2002, Vol. 37, No. 5, pp. 367-378.									
If you wis	h to a	dd addi	ional non-	-patent literature	document	citation informa	tion please click the Add	button	-		
					EXAMIN	ER SIGNATUI	RE				
Examiner	Sign	ature	/Sha	wquia Young/			Date Considered	01/29/2009			

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

See Kind Codes of USPTO Patent Documents at <a href="https://www.USPTO.GOV">www.USPTO.GOV</a> or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.